The cardiorenal syndrome: Recognition and treatment

Italian Heart Journal

Volumn 6, Issue 12, 2005, Pages 941-945

  Fedele, Francesco ^a   De Luca, Leonardo ^a   Gheorghiade, Mihai ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Cardiorenal syndrome; Heart failure; Renal dysfunction; Treatment

Indexed keywords

CONGESTIVE HEART FAILURE; HUMAN; KIDNEY FAILURE; PROGNOSIS; REVIEW; SYNDROME;

HEART FAILURE, CONGESTIVE; HUMANS; PROGNOSIS; RENAL INSUFFICIENCY; SYNDROME;

EID: 33646084876     PISSN: 1129471X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Bongartz LG, Cramer MJ, Doevendans PA, Joles JA, Braam B. The severe cardiorenal syndrome: "Guyton revisited". Eur Heart J 2005; 26: 11-7.
2. Firth JD, Raine AE, Ledingham JG. Raised venous pressure: a direct cause of renal sodium retention in oedema? Lancet 1988; 1: 1033-5.
3. Forman DE, Butler J, Wang Y, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 2004; 43: 61-7.
4. Gottlieb SS, Abraham W, Butler J, et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail 2002; 8: 136-41.
5. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
6. Hillege HL, Girbes ARJ, de Kam PJ, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000; 102: 203-10.
7. Dries DL, Exner DV, Domanski MJ, et al. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000; 35: 681-9.
8. Smith GL, Vaccarino V, Kosiborod M, et al. Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure? J Card Fail 2003; 9: 13-25.
9. Fonarow GC, Adams KF Jr, Abraham WT, et al, for the ADHERE Scientific Advisory Committee, Study Group, and Investigators. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 2005; 293: 572-80.
10. Adams KF Jr, Fonarow GC, Emerman CL, et al, for the ADHERE Scientific Advisory Committee and Investigators. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100 000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005; 149: 209-16.
11. Felker GM, Leimberger JD, Califf RM, et al. Risk stratification after hospitalization for decompensated heart failure. J Card Fail 2004; 10: 460-6.
12. Kerzner R, Gage BF, Freedland KE, Rich MW. Predictors of mortality in younger and older patients with heart failure and preserved or reduced left ventricular ejection fraction. Am Heart J 2003; 146: 286-90.
13. Krumholz HM, Chen YT, Vaccarino V, et al. Correlates and impact on outcomes of worsening renal function in patients ≥65 years of age with heart failure. Am J Cardiol 2000; 85: 1110-3.
14. Shlipak MG. Pharmacotherapy for heart failure in patients with renal insufficiency. Ann Intern Med 2003; 138: 917-24.
15. Schulz R, Rose J, Martin C, Brodde OE, Heusch G. Development of short-term myocardial hibernation: its limitation by the severity of ischemia and inotropic stimulation. Circulation 1993; 88: 684-95.
16. Indolfi C, Piscione F, Perrone-Filardi P, et al. Inotropic stimulation by dobutamine increases left ventricular regional function at the expense of metabolism in hibernating myocardium. Am Heart J 1996; 132: 542-9.
17. Ungar A, Fumagalli S, Marini M, et al. Renal but not systemic, hemodynamic effects of dopamine are influenced by the severity of congestive heart failure. Crit Care Med 2004; 32: 1125-9.
18. Bichet DG, Kortas C, Mettauer B, et al. Modulation of plasma and platelet vasopressin by cardiac function in patients with heart failure. Kidney Int 1986; 29: 1188-96.
19. Tobian I, Coffee K, Ferreira D, Meuli J. The effect of renal perfusion pressure on net transport of sodium out of distal tubular urine as studied with stop-flow technique. J Clin Invest 1964; 43: 118-28.
20. Nieminen MS, Bohm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26: 384-416.
21. Latini R, Tognoni G, Maggioni AP, et al. Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96 712 randomized patients. Angiotensin-Converting Enzyme Inhibitor Myocardial Infarction Collaborative Group. J Am Coll Cardiol 2000; 35: 1801-7.
22. Weinfeld MS, Chertow GM, Stevenson LW. Aggravated renal dysfunction during intensive therapy for advanced heart failure. Am Heart J 1999; 138: 285-90.
23. Knight EL, Glynn RJ, McIntyre KM, Mogun H, Avorn J. Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the Studies of Left Ventricular Dysfunction (SOLVD). Am Heart J 1999; 138: 849-55.
24. Philbin EF, Cotto M, Rocco TA Jr, Jenkins PL. Association between diuretic use, clinical response, and death in acute heart failure. Am J Cardiol 1997; 80: 519-22.
25. Cooper HA, Dries DL, Davis CE, Shen YL, Domanski MJ. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 1999; 100: 1311-5.
26. Butler J, Forman DE, Abraham WT, et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 2004; 147: 331-8.
27. Leier CV. Renal roadblock in managing low output heart failure. Crit Care Med 2004; 32: 1228-9.
28. Shlipak MG, Massie BM. The clinical challenge of cardiorenal syndrome. Circulation 2004; 110: 1514-7.
29. Wang DJ, Dowling TC, Meadows D, et al. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation 2004; 110: 1620-5.
30. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005; 111: 1487-91.
31. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 2005; 293: 1900-5.
32. Gottlieb SS, Brater DC, Thomas I, et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 2002; 105: 1348-53.
33. Gheorghiade M, Gattis WA, O'Connor CM, et al, for the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004; 291: 1963-71.